

Ronald F Van Vollenhoven

List of Publications by Citations

Source: <https://exaly.com/author-pdf/688412/ronald-f-van-vollenhoven-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

13,918
citations

38
h-index

117
g-index

169
ext. papers

18,120
ext. citations

6.7
avg, IF

6.09
L-index

#	Paper	IF	Citations
114	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
113	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977 ⁴		1649
112	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3918-30		944
111	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699 ^{3,4}		851
110	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
109	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
108	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 508-19	59.2	658
107	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
106	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16039	51.1	422
105	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
104	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
103	Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. <i>Journal of Rheumatology</i> , 2010 , 37, 558-67	4.1	212
102	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
101	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	40	196
100	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
99	Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1263-72		175
98	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173

97	Treatment of rheumatoid arthritis: state of the art 2009. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 531-41	8.1	170
96	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , 2018 , 392, 1330-1339	4.0	161
95	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
94	Sex differences in rheumatoid arthritis: more than meets the eye. <i>BMC Medicine</i> , 2009 , 7, 12	11.4	146
93	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. <i>Journal of Rheumatology</i> , 2015 , 42, 1761-6	4.1	142
92	Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 469-75	2.4	128
91	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1081-91	2.4	119
90	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 52-8	2.4	88
89	Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1102-9	2.4	76
88	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2174-83	9.5	75
87	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1607-1620	9.5	56
86	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1751-1761	9.5	55
85	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019 , 9, e025687	3	49
84	Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. <i>Arthritis Care and Research</i> , 2018 , 42, 226-34	4.7	47
83	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
82	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1031-41	3.9	46
81	Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1500-3		43
80	Treat-to-target in rheumatoid arthritis - are we there yet?. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 180-186		42

79	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	40
78	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , 2021 , 3, e778-e788	14.2	40
77	Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response. <i>Rheumatology</i> , 2013 , 52, 847-55	3.9	39
76	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
75	Advances in the treatment of rheumatoid arthritis. <i>F1000prime Reports</i> , 2014 , 6, 31		36
74	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1094-101	2.4	35
73	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017 , 4, e000192	4.6	34
72	Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2017 , 3, e000458	5.9	34
71	Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 23-31	4	34
70	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163	4.6	34
69	Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. <i>Arthritis Research</i> , 2003 , 5, R347-51		32
68	Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. <i>RMD Open</i> , 2016 , 2, e000213		30
67	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017 , 56, 541-549	3.9	28
66	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016 , 18, 50	5.7	27
65	Unresolved issues in biologic therapy for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 205-15	8.1	27
64	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1567-70	2.4	25
63	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018 , 18, 528-538	3.5	25
62	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24

61	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology, The</i> , 2020 , 2, e583-e585	14.2	23
60	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017 , 69, 953-963	9.5	22
59	Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 70-2	8.1	22
58	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 761-768	9.5	22
57	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
56	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017 , 3, e000371	5.9	19
55	Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial. <i>BMC Medicine</i> , 2015 , 13, 247	11.4	19
54	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2016 , 2, e000197	5.9	19
53	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
52	The relationship between remission and health-related quality of life in a cohort of SLE patients. <i>Rheumatology</i> , 2019 , 58, 628-635	3.9	18
51	Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging. <i>RMD Open</i> , 2015 , 1, e000106	5.9	15
50	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
49	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. <i>RMD Open</i> , 2016 , 2, e000262	5.9	15
48	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. <i>Rheumatology</i> , 2021 , 60, 207-216	3.9	15
47	B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies. <i>Human Antibodies</i> , 2004 , 13, 63-68	1.3	14
46	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 157-168	5.4	14
45	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017 , 44, 162-169	4.1	13
44	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13

43	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. <i>BMJ Open</i> , 2017 , 7, e016154	3	11
42	Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. <i>Arthritis Care and Research</i> , 2016 , 68, 562-9	4.7	11
41	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
40	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016 , 2, e000323	5.9	11
39	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
38	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e163-e173	14.2	9
37	New and future agents in the treatment of rheumatoid arthritis. <i>Discovery Medicine</i> , 2010 , 9, 319-27	2.5	9
36	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. <i>Journal of Rheumatology</i> , 2019 , 46, 555-563	4.1	8
35	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7
34	Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2855-60	9.5	7
33	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
32	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
31	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000287	4.6	7
30	Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. <i>RMD Open</i> , 2017 , 3, e000369	5.9	6
29	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020 , 6,	5.9	6
28	Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. <i>Lupus Science and Medicine</i> , 2018 , 5, e000288	4.6	6
27	The association between diet and glucocorticoid treatment in patients with SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000135	4.6	5
26	Does disease activity at start of biologic therapy influence work-loss in RA patients?. <i>Rheumatology</i> , 2016 , 55, 729-34	3.9	5

25	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020 , 59, 1842-1852	3.9	5
24	Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 1065-1071	2.2	5
23	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
22	Response to: MBDA: what is it good for? By Yazici et al. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e73	2.4	4
21	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
20	New therapeutic approaches in rheumatoid arthritis. <i>Presse Medicale</i> , 2016 , 45, e179-92	2.2	4
19	Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2019 , 42, 34-46	1.3	3
18	Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort. <i>International Journal of Rheumatology</i> , 2018 , 2018, 9152480	2	3
17	94. Tocilizumab in Patients with Rheumatoid Arthritis and Rates of Malignancy: Results from Long-Term Extension Clinical Trials. <i>Rheumatology</i> , 2014 , 53, i91-i92	3.9	3
16	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
15	Methotrexate for Prevention of Cardiovascular Events. <i>New England Journal of Medicine</i> , 2019 , 380, 2276-2277	3.9	2
14	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
13	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013 , 52, i44-i55	3.9	2
12	What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2059-2068	9.5	2
11	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
10	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	2
9	Does disease activity at the start of biologic therapy influence health care costs in patients with RA?. <i>Rheumatology</i> , 2015 , 54, 1472-7	3.9	1
8	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7	1

7	Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study. <i>Journal of Rheumatology</i> , 2021 ,	4.1	1
6	Infliximab in the treatment of rheumatoid arthritis. <i>Aging Health</i> , 2006 , 2, 19-33		1
5	Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
4	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021 , 7,	5.9	1
3	Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. <i>Rheumatology</i> , 2021 ,	3.9	1
2	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021 , 31, 534-542	3.3	1
1	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. <i>Rheumatology</i> , 2021 , 60, 2217-2222	3.9	